| Previous Close | 120.6500 |
| Open | 120.9600 |
| Bid | 120.3200 x 100 |
| Ask | 120.3800 x 2000 |
| Day's Range | 120.3207 - 120.4850 |
| 52 Week Range | 99.8100 - 120.8500 |
| Volume | 12,402 |
| Avg. Volume | 125,206 |
| Net Assets | 9.88B |
| NAV | 117.66 |
| PE Ratio (TTM) | N/A |
| Yield | 0.79% |
| YTD Return | 11.74% |
| Beta (3y) | 1.06 |
| Expense Ratio (net) | 0.07% |
| Inception Date | 2006-08-17 |
- Market Realist•17 days ago
BioMarin Expects These Drugs to Generate Steady Revenues
In 2016, BioMarin Pharmaceuticals’ (BMRN) Naglazyme generated revenues of around $297 million, a ~2% year-over-year (or YoY) decline.
- Motley Fool•24 days ago
3 Top Mid-Cap Growth ETFs for 2017
These mid-cap growth ETFs can allow you to diversify your risk and achieve strong long-term growth.
- Motley Fool•29 days ago
Best Growth ETFs for 2017 and Beyond
Growth stock ETFs can allow you to profit from rapidly-growing companies while diversifying your risk.
